ACell’s principal management team comprises a group of leaders committed to advancing regenerative medicine for wound and surgical patients with unmet medical needs.
Patrick A. McBrayer
President and Chief Executive Officer
Patrick A. McBrayer joined ACell as President and Chief Executive Officer in 2016. Mr. McBrayer is on the Board of Directors of Misonix Inc (NASDAQ:MSON), which markets therapeutic ultrasound medical devices world-wide. He has recently advised medical device companies in spine, orthopedics and biotechnology. Mr. McBrayer was President and Chief Executive Officer of AxioMed Spine Corporation until the company was acquired in 2014. AxioMed focused on restoring the native function of the spine with the company’s Freedom total disc spine technology.
Prior to AxioMed, Mr. McBrayer was Chief Executive Officer of Xylos Corporation, a medical biomaterials company. He was also a Founder of Transave Inc. (now Insmed Inc.), a biotechnology company focused on the site specific treatment of lung disease. Prior to joining Xylos, Mr. McBrayer served as President and CEO of Exogen, Inc., a company focused on the non-invasive treatment of musculoskeletal injury and disease, which was acquired by Smith & Nephew, Inc. in 1999.
Previously, Mr. McBrayer was President and CEO of Osteotech, Inc., a worldwide leader in tissue technology (acquired by Medtronic Inc.). He has been responsible for a number of private placements, as well as Osteotech and Exogen’s public offerings. He received the Thomas Alva Edison Patent Award in 1998 for a biological implant for bone repair that is now a market leading product. Prior to joining Osteotech, Mr. McBrayer held positions of increasing responsibility for Johnson & Johnson, Inc.
He has over 20 years healthcare senior management experience and served as an Infantry Officer Company Commander in the U.S. Army prior to beginning his business career. Mr. McBrayer is a graduate of the United States Military Academy at West Point.
Sally L. Maher
Interim Chief Operating Officer
Sally Maher joined ACell as Interim Chief Operating Officer in 2018. Ms. Maher continues to serve on the ACell Board of Directors. She previously served as Vice President of Regulatory and Clinical Affairs at Edwards Lifesciences, Critical Care. She has more than 25 years of medical device and combination product experience in regulatory, clinical, reimbursement, healthcare compliance, and product development.
Prior to joining Edwards, Ms. Maher held various Senior Vice President roles at Smith & Nephew’s Advanced Surgical Products Division including: Regulatory and Clinical Affairs, Reimbursement and Healthcare Economics, Healthcare Compliance, Research and Development, and New Business Development. Prior to Smith & Nephew, Ms. Maher worked in regulatory, quality, and clinical roles for various organizations including Johnson & Johnson, Pfizer, and the US Food and Drug Administration. She received a bachelor’s degree from Ohio Wesleyan University, and a law degree from the University of Baltimore.
Chief Financial Officer
Edward O’Brien has served as our Chief Financial Officer since 2008. From 2008 until 2013, Mr. O’Brien also served as the Chief Financial Officer of Credit Management Solutions, Inc., a financial services technology company. Prior to joining ACell, Mr. O’Brien held the position of Executive Vice President, Chief Financial Officer and Corporate Controller for Transaction Network Services, Inc. from 1999 through 2007.
Thomas W. Gilbert, Ph.D.
Chief Science Officer
Dr. Gilbert has served as Chief Science Officer at ACell since 2015, after serving as ACell’s Vice President, Research and Development since 2012. Previously, Dr. Gilbert was Assistant Professor of Surgery, Cardiothoracic Surgery, and Bioengineering at the University of Pittsburgh and was a faculty member of the McGowan Institute for Regenerative Medicine. His research includes the study of processing and use of extracellular matrix scaffold materials (including urinary bladder matrix) for development of regenerative medicine strategies in a variety of body systems. Dr. Gilbert has co-authored more than fifty peer-reviewed articles, several book chapters, and has applied for several patents related to ECM technology. His funding sources included the National Institutes of Health and the National Science Foundation. He has also worked as an Metallurgist for the Perryman Company in Houston, PA. Dr. Gilbert has a BS in Materials Science and Engineering from Carnegie Mellon University and a PhD in Bioengineering from the University of Pittsburgh.
Vice President and Chief Compliance Officer
Bill Hrubes has served as Vice President and Chief Compliance Officer at ACell since 2015, after serving as Senior Director of Compliance and Risk Management since 2014. He has more than 15 years of experience in the development, implementation, and management of compliance and ethics programs in the life sciences industry. Mr. Hrubes previously served as the Compliance Officer for the Joint Reconstruction business of Johnson & Johnson. He has held other leadership roles in compliance and risk management at companies including Smith & Nephew, Novation, Gambro, and Fresenius Medical Care North America.
Vice President, Administrative Services
Patty Meehan has served as ACell’s Vice President, Administrative Services since 2002. She brings more than 30 years of administrative leadership in the financial and healthcare industry to the organization. Before joining ACell, Ms. Meehan was Director of Administration at CMSI and Perpetual Leasing Corp. She attended the College of Notre Dame of Maryland.
Vice President, Marketing
David Elliot joined ACell as Vice President, Marketing in 2015. He has more than 20 years of experience in commercialization, market development, sales and marketing leadership, and strategic planning. Mr. Elliot previously served as Vice President, Academic Affairs and Marketing Services at St. Jude Medical. He has held leadership positions at a range of medical device companies including Tyrx, Inc., Valam, VistaCare (now Odyssey/Gentiva), VasClip, Guidant, and Eli Lilly.
Vice President, Sales
Brad Adams joined ACell as Vice President, Sales in 2016. He has more than 20 years of senior healthcare management experience, most recently serving as Executive Vice President, Commercial for Smith & Nephew, Inc. Prior to Smith & Nephew, Mr. Adams was Vice President of Sales for Healthpoint Biotherapeutics, Inc. and previously served as Vice President of Worldwide Sales for two Johnson & Johnson companies: Animas, Inc. and Therakos, Inc. Mr. Adams also has experience in hospital administration and received his master’s degree in Health Administration from The Medical College of Virginia. A graduate of the Virginia Military Institute, he served as an Officer in the United States Army.
General Counsel and Vice President, Human Resources
Chris Branch has served as General Counsel and Vice President, Human Resources since 2018 after joining ACell as Deputy General Counsel in 2013. Prior to ACell, he was Chief Litigation Counsel for Catalyst Health Solutions. Mr. Branch has more than 15 years of experience in outside counsel and in-house counsel roles and a history of executing strategic and tactical legal and business initiatives that minimize risk and drive revenue. He holds a law degree from Georgetown University Law Center and a Bachelor of Arts in Public Policy from Duke University.
Vice President, International and Business Development
Nino Pionati joined ACell in 2018 as Vice President, International and Business Development. Prior to ACell, Mr. Pionati was Chief Strategy and Marketing Officer at Alliqua Biomedical. Prior to his role at Alliqua, he served as Vice President of Marketing for Bayer HealthCare Pharmaceutical’s Essure portfolio and a member of the Global Franchise and Women’s Health Care Leadership teams. Prior to joining Bayer, Mr. Pionati spent over 14 years at ConvaTec and Bristol Myers Squibb, where he held several global marketing positions at the corporate level, including President of Global Marketing, Business Development and International and President of the Intercontinental Region. He also progressed through positions of increasing responsibility during his 13 years at Johnson & Johnson, and co-led the strategic development of internally-backed startup, J & J Independence Technologies, including sales, service, clinical, regulatory and marketing. He holds an MBA from the University of Pittsburgh’s Katz School of Business and a Bachelors of Commerce in Marketing from Concordia University of Montreal.